Immuno-PET: Design options and clinical proof-of-concept
Radioimmunoconjugates have been used for over 30 years in nuclear medicine applications. In the last few years, advances in cancer biology knowledge have led to the identification of new molecular targets specific to certain patient subgroups. The use of these targets in targeted therapies approache...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1026083/full |
| _version_ | 1811241603194421248 |
|---|---|
| author | Alexandre Lugat Clément Bailly Clément Bailly Michel Chérel Michel Chérel Caroline Rousseau Caroline Rousseau Françoise Kraeber-Bodéré Françoise Kraeber-Bodéré Caroline Bodet-Milin Caroline Bodet-Milin Mickaël Bourgeois Mickaël Bourgeois Mickaël Bourgeois |
| author_facet | Alexandre Lugat Clément Bailly Clément Bailly Michel Chérel Michel Chérel Caroline Rousseau Caroline Rousseau Françoise Kraeber-Bodéré Françoise Kraeber-Bodéré Caroline Bodet-Milin Caroline Bodet-Milin Mickaël Bourgeois Mickaël Bourgeois Mickaël Bourgeois |
| author_sort | Alexandre Lugat |
| collection | DOAJ |
| description | Radioimmunoconjugates have been used for over 30 years in nuclear medicine applications. In the last few years, advances in cancer biology knowledge have led to the identification of new molecular targets specific to certain patient subgroups. The use of these targets in targeted therapies approaches has allowed the developments of specifically tailored therapeutics for patients. As consequence of the PET-imaging progresses, nuclear medicine has developed powerful imaging tools, based on monoclonal antibodies, to in vivo characterization of these tumor biomarkers. This imaging modality known as immuno-positron emission tomography (immuno-PET) is currently in fastest-growing and its medical value lies in its ability to give a non-invasive method to assess the in vivo target expression and distribution and provide key-information on the tumor targeting. Currently, immuno-PET presents promising probes for different nuclear medicine topics as staging/stratification tool, theranostic approaches or predictive/prognostic biomarkers. To develop a radiopharmaceutical drug that can be used in immuno-PET approach, it is necessary to find the best compromise between the isotope choice and the immunologic structure (full monoclonal antibody or derivatives). Through some clinical applications, this paper review aims to discuss the most important aspects of the isotope choice and the usable proteic structure that can be used to meet the clinical needs. |
| first_indexed | 2024-04-12T13:38:41Z |
| format | Article |
| id | doaj.art-c494c40b0e3b4e859e00d8d1410fc8c2 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T13:38:41Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-c494c40b0e3b4e859e00d8d1410fc8c22022-12-22T03:30:55ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-10-01910.3389/fmed.2022.10260831026083Immuno-PET: Design options and clinical proof-of-conceptAlexandre Lugat0Clément Bailly1Clément Bailly2Michel Chérel3Michel Chérel4Caroline Rousseau5Caroline Rousseau6Françoise Kraeber-Bodéré7Françoise Kraeber-Bodéré8Caroline Bodet-Milin9Caroline Bodet-Milin10Mickaël Bourgeois11Mickaël Bourgeois12Mickaël Bourgeois13Nantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceNantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceNuclear Medicine Department, University Hospital, Nantes, FranceNantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceDepartment of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO) – Site Gauducheau, Saint-Herblain, FranceNantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceDepartment of Nuclear Medicine, Institut de Cancérologie de l'Ouest (ICO) – Site Gauducheau, Saint-Herblain, FranceNantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceNuclear Medicine Department, University Hospital, Nantes, FranceNantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceNuclear Medicine Department, University Hospital, Nantes, FranceNantes-Angers Cancer Research Center CRCI2NA, University of Nantes, INSERM UMR1307, CNRS-ERL6075, Nantes, FranceNuclear Medicine Department, University Hospital, Nantes, FranceARRONAX Cyclotron, Saint-Herblain, FranceRadioimmunoconjugates have been used for over 30 years in nuclear medicine applications. In the last few years, advances in cancer biology knowledge have led to the identification of new molecular targets specific to certain patient subgroups. The use of these targets in targeted therapies approaches has allowed the developments of specifically tailored therapeutics for patients. As consequence of the PET-imaging progresses, nuclear medicine has developed powerful imaging tools, based on monoclonal antibodies, to in vivo characterization of these tumor biomarkers. This imaging modality known as immuno-positron emission tomography (immuno-PET) is currently in fastest-growing and its medical value lies in its ability to give a non-invasive method to assess the in vivo target expression and distribution and provide key-information on the tumor targeting. Currently, immuno-PET presents promising probes for different nuclear medicine topics as staging/stratification tool, theranostic approaches or predictive/prognostic biomarkers. To develop a radiopharmaceutical drug that can be used in immuno-PET approach, it is necessary to find the best compromise between the isotope choice and the immunologic structure (full monoclonal antibody or derivatives). Through some clinical applications, this paper review aims to discuss the most important aspects of the isotope choice and the usable proteic structure that can be used to meet the clinical needs.https://www.frontiersin.org/articles/10.3389/fmed.2022.1026083/fullnuclear medicineimmuno-PETdiagnosistheranosticmonoclonal antibody |
| spellingShingle | Alexandre Lugat Clément Bailly Clément Bailly Michel Chérel Michel Chérel Caroline Rousseau Caroline Rousseau Françoise Kraeber-Bodéré Françoise Kraeber-Bodéré Caroline Bodet-Milin Caroline Bodet-Milin Mickaël Bourgeois Mickaël Bourgeois Mickaël Bourgeois Immuno-PET: Design options and clinical proof-of-concept Frontiers in Medicine nuclear medicine immuno-PET diagnosis theranostic monoclonal antibody |
| title | Immuno-PET: Design options and clinical proof-of-concept |
| title_full | Immuno-PET: Design options and clinical proof-of-concept |
| title_fullStr | Immuno-PET: Design options and clinical proof-of-concept |
| title_full_unstemmed | Immuno-PET: Design options and clinical proof-of-concept |
| title_short | Immuno-PET: Design options and clinical proof-of-concept |
| title_sort | immuno pet design options and clinical proof of concept |
| topic | nuclear medicine immuno-PET diagnosis theranostic monoclonal antibody |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.1026083/full |
| work_keys_str_mv | AT alexandrelugat immunopetdesignoptionsandclinicalproofofconcept AT clementbailly immunopetdesignoptionsandclinicalproofofconcept AT clementbailly immunopetdesignoptionsandclinicalproofofconcept AT michelcherel immunopetdesignoptionsandclinicalproofofconcept AT michelcherel immunopetdesignoptionsandclinicalproofofconcept AT carolinerousseau immunopetdesignoptionsandclinicalproofofconcept AT carolinerousseau immunopetdesignoptionsandclinicalproofofconcept AT francoisekraeberbodere immunopetdesignoptionsandclinicalproofofconcept AT francoisekraeberbodere immunopetdesignoptionsandclinicalproofofconcept AT carolinebodetmilin immunopetdesignoptionsandclinicalproofofconcept AT carolinebodetmilin immunopetdesignoptionsandclinicalproofofconcept AT mickaelbourgeois immunopetdesignoptionsandclinicalproofofconcept AT mickaelbourgeois immunopetdesignoptionsandclinicalproofofconcept AT mickaelbourgeois immunopetdesignoptionsandclinicalproofofconcept |